Keynote Lectures and Interviews:

The followings are the keynote lectures and interviews of the researchers working in the areas of ROS1+ lung cancer. It helped me to understand this disease tremendously. Hope it will help you.


This session is the talks given by the scientists on Targeted Oncology.

Alexander Drilon, MD and Justin Gainor, MD
Memorial Sloan Kettering Cancer Center and Massachusetts General Hospital

Aug 23, 2018
Sequencing therapy in ALK/ROS1-Rearraged NSCLC

ALK/ROS1-Rearranged NSCLC: Approaching Therapy

Emerging Predictive Biomarkers in NSCLC

Molecular Testing in Stage IV Lung Cancer


Bonnie J Addario Lung Cancer Foundation

August 6, 2018
Panel members are Dr. Ross Camidge, Dr. Chad Rusthoven and Dr. Dara Aisner and Janet Freeman-Daily. The Importance of a Multidisciplinary Team


Janet Freeman-Daily, Stage IV Lung Cancer Survivor; Patient Advocate

Programs featuring Janet Freeman-Daily

******************                                                                                                                             In this section, new findings on ROS1+ NSCLC published from Colorado Cancer Blogs are summarized here.

Ross Camidge, MD, PhD

June 29, 2018
Dr. Camidge on the ALEX Trial in Patients With ALK+ NSCLC

Jun 2, 2018
Updated Phase 1 results of crizotinib against MET-amplified non-small cell lung cancer

June 23, 2013
Dr. Camidge on Crizotinib as a ROS1 Inhibitor in NSCLC

Tejas Patil, MD

Jul 10, 2018                                                                                                                                     Brain metastases common and difficult to treat in ROS1 lung cancer,

Robert C. Doebele, MD, PhD

Apr 10, 2018                                                                                                                                     Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers,

*****************                                                                                                                          Alice T. Shaw, MD PhD

March 29, 2018
Shaw Pattern of Resistance in ALK Positive NSCLC,

Feb 12, 2018
EML4/ALK and ROS-1: How do we sequence therapies,

June 29, 2017
Q&A With Dr. Shaw: ALK/ROS1 Inhibition in Patients With Non-small Cell Lung Cancer

June 14, 2017
Next generation of ALK TKI inhibitors for treatment of advanced ALK-positive NSCLC,

Jan17, 2017
Discussion on Alectinib as First-Line Therapy in Lung Cancer,

Aug 19,2015
Targeted Therapies in Lung Cancer 2.0 – Advances and Promises,

March 10, 2014
Molecular Targetsin NSCLC,

Oct 28, 2013
ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies

July 19, 2013
Compares Crizotinib and Chemotherapy in NSCLC,

Jan 21, 2013
Advances in Targeted Therapies for Lung Cancer,

Oct 24, 2011
Targeting of NSCLC in 2011,

July 11, 2011
Koch Institute Delication Ceremony,

Lecia V Sequist, MD, MPH

June 17, 2017
Diagnostic testing for genetic mutations in lung cancer,

June 17, 2015
Understanding mutations in lung cancer,